Biocon Limited enters into a settlement agreement with Celgene Corp

Biocon Limited and its subsidiaries Biocon Pharma Limited and Biocon Pharma Inc. ("Biocon") has entered into a confidential settlement agreement with Celgene Corporation (Celgene), a wholly owned subsidiary of Bristol Myers Squibb (NYSE: BMY), relating to patents for REVLIMID® (lenalidomide).

Shares of Biocon Ltd. was last trading in BSE at Rs. 357.15 as compared to the previous close of Rs. 361.35. The total number of shares traded during the day was 29555 in over 972 trades.

The stock hit an intraday high of Rs. 363.9 and intraday low of 354.55. The net turnover during the day was Rs. 10561758.

Source : Equity Bulls

Keywords